[
    {
        "content": "* Exelixis announces third quarter 2017 financial results and provides corporate update",
        "date": "11012017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis reports Q3 earnings per share $0.26 "
    },
    {
        "content": "Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial  sending the company's shares soaring 31 percent.",
        "date": "10162017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "Exelixis drug improves overall survival in liver cancer patients "
    },
    {
        "content": "* Shares jump 31 pct (Adds details  company comment  updates shares))",
        "date": "10162017",
        "name": "Exelixis Inc",
        "news_type": "normal",
        "symbol": "EXEL",
        "title": "UPDATE 3-Exelixis drug improves overall survival in liver cancer patients "
    },
    {
        "content": "* Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma",
        "date": "10162017",
        "name": "Exelixis Inc",
        "news_type": "normal",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial "
    },
    {
        "content": "Oct 16 Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer.",
        "date": "10162017",
        "name": "Exelixis Inc",
        "news_type": "normal",
        "symbol": "EXEL",
        "title": "Exelixis cancer drug meets key goal in late-stage trial "
    },
    {
        "content": "* Exelixis to receive milestone payment from Bristol-Myers Squibb for submission of clinical trial authorization for ROR\u03b3t inverse agonist program",
        "date": "10042017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis to receive milestone payment from Bristol-Myers Squibb "
    },
    {
        "content": "* ANNOUNCED ON SUNDAY  RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA",
        "date": "09112017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial "
    },
    {
        "content": "* Exelixis submits U.S. Supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer Source text for Eikon: Further company coverage:",
        "date": "08162017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer "
    },
    {
        "content": "* Exelixis announces settlement of dispute with Genentech regarding companies\u2019 collaboration agreement for Cobimetinib",
        "date": "07202017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces settlement of dispute with Genentech "
    },
    {
        "content": "* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx  versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma",
        "date": "07102017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis  Bristol-Myers Squibb initiate phase 3 trial "
    },
    {
        "content": "* IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA",
        "date": "06192017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib "
    },
    {
        "content": "* Exelixis announces independent radiology committee review confirms results from cabosun  the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma",
        "date": "06192017",
        "name": "Exelixis Inc",
        "news_type": "normal",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN "
    },
    {
        "content": "* Exelixis Inc announces initiation of Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors Source text for Eikon: Further company coverage:",
        "date": "06122017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces initiation of early-stage trial of combination drug "
    },
    {
        "content": "* Exelixis announces first quarter 2017 financial results and provides corporate update",
        "date": "05012017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis Q1 earnings per share $0.05 "
    },
    {
        "content": "* Exelixis further reduces indebtedness by repaying silicon valley bank term loan",
        "date": "03292017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis further reduces indebtedness by repaying Silicon Valley Bank term loan "
    },
    {
        "content": "* Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma",
        "date": "03062017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis' cabozantinib granted orphan drug designation "
    },
    {
        "content": "* Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors",
        "date": "02272017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces clinical trial collaboration with Roche "
    },
    {
        "content": "* Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors",
        "date": "02172017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab "
    },
    {
        "content": "* Exelixis and Takeda enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in Japan",
        "date": "01302017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis and Takeda enter into exclusive licensing agreement "
    },
    {
        "content": "* Update on dispute between Exelixis and Genentech  a member of the Roche group",
        "date": "01092017",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration\u007f "
    },
    {
        "content": "* Exelixis announces third quarter and year to date 2016 financial results and provides corporate update",
        "date": "11032016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces Q3 and YTD 2016 financial results "
    },
    {
        "content": "* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib",
        "date": "10112016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib "
    },
    {
        "content": "* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma",
        "date": "10102016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib "
    },
    {
        "content": "* Says findings will be presented during a poster discussion session on October 9",
        "date": "10072016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces Phase 1 trial results for Cabozantinib in combination with Nivolumab in advanced Genitourinary tumors "
    },
    {
        "content": "* Exelixis elects Julie Anne Smith to its board of directors  Source text for Eikon:  Further company coverage:",
        "date": "09262016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis elects Julie Anne Smith to board "
    },
    {
        "content": "* Exelixis announces redemption of all remaining 4.25% convertible senior subordinated notes due 2019",
        "date": "08242016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis announces redemption of remaining 4.25 convertible senior subordinated notes "
    },
    {
        "content": "* Exelixis announces second quarter and year to date 2016 financial results and provides corporate update",
        "date": "08032016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis Q2 loss per share $0.16 "
    },
    {
        "content": "* Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults",
        "date": "07222016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Ipsen and Exelixis receive positive CHMP opinion for Cabometyx "
    },
    {
        "content": "* Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting",
        "date": "06062016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis  Ipsen post results from advanced renal cell carcinoma study "
    },
    {
        "content": "* Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",
        "date": "06062016",
        "name": "Exelixis Inc",
        "news_type": "normal",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX "
    },
    {
        "content": "* reported positive top line results from Cabosun phase 2 trial of Cabozantinib in patients with untreated advanced renal cell carcinoma",
        "date": "05232016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Ipsen SA says Exelixis Inc reported positive top-line results from Cabosun phase 2 trial of Cabozantinib "
    },
    {
        "content": "* Exelixis announces first quarter 2016 financial results and provides corporate update",
        "date": "05042016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis reports Q1 loss per share $0.27 "
    },
    {
        "content": "* Exelixis announces FDA approval of Cabometyx(TM) (Cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy",
        "date": "04252016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis gets FDA approval for Cabometyx tablets "
    },
    {
        "content": "* Announces that its partner Exelixis obtained FDA approval of CABOMETYX (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",
        "date": "04262016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets "
    },
    {
        "content": "* Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in regions outside the United States  Canada and Japan",
        "date": "03012016",
        "name": "Exelixis Inc",
        "news_type": "topStory",
        "symbol": "EXEL",
        "title": "BRIEF-Exelixis and Ipsen enter into exclusive licensing agreement "
    }
]